高危筛查乳腺MRI中BI-RADS 3类病变的频率与癌症检出率
该研究回顾2011至2015年连续乳腺MRI筛查 examinations,比较基线与非基线检查中BI-RADS 3类的频率和癌症检出率。基线检查BI-RADS 3类频率为8%(82/983),高于非基线检查的2%(120/5689)(p<0.001)。总体BI-RADS 3类病变癌症检出率为6%(13/202),其中12/13为0期或I期;基线癌症检出率为2%(2/82),非基线为9%(11/120)(p=0.056)。
要点
- 基线乳腺MRI筛查的BI-RADS 3类评估率(8%)显著高于非基线检查(2%)。
- BI-RADS 3类病变总体癌症检出率为6%,多数为早期(0期或I期)。
- 13例癌症中10例在6个月随访MRI或之前升级。
诊断标准与关键数值
- 总体BI-RADS 3类检查中癌症检出率为6%(13/202),其中12/13为0期或I期。
- 基线检查BI-RADS 3类癌症检出率为2%(2/82),非基线检查为9%(11/120)(p=0.056)。
- 基线检查BI-RADS 3类评估率为8%(82/983),非基线检查为2%(120/5689)(p<0.001)。
临床应用与阅片要点
- 基线筛查乳腺MRI中BI-RADS 3类评估率较高,非基线检查中较低。
- BI-RADS 3类病变随访诊断的癌症多为早期,多数在6个月随访检查或之前诊断。
- 作者认为,审慎使用时短期随访MRI是识别早期乳腺癌并避免良性病变不必要活检的合适方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to evaluate the frequency and cancer yield of BI-RADS category 3 lesions in baseline versus nonbaseline (those with at least one prior) MRI screening examinations. MATERIALS AND METHODS. Consecutive MRI screening examinations performed from 2011 through 2015 were reviewed. Pearson and Wilcoxon tests were used to examine differences in age, breast density, screening indication, background parenchymal enhancement, and cancer yield between baseline and nonbaseline MRI BI-RADS category 3 assessments. Multivariate logistic regression models based on generalized estimating equations were used to assess the odds of receiving a BI-RADS 3 assessment as a function of the variables. RESULTS. Of 6672 MRI screening examinations of 3214 patients, 202 examinations (3%) were assessed BI-RADS category 3. Among baseline examinations, 8% (82/983) were assessed BI-RADS 3, compared with 2% (120/5689) of nonbaseline examinations (p < 0.001). Among the total BI-RADS 3 examinations, 6% (13/202) yielded malignancy of the lesion that had been assessed BI-RADS 3; 12 of 13 cancers were stage 0 or I at diagnosis. The cancer yield of BI-RADS 3 at baseline examinations was 2% (2/82), compared with 9% (11/120) for nonbaseline examinations (p = 0.056). Ten of 13 examinations were upgraded at or before 6-month follow-up MRI. CONCLUSION. Baseline screening breast MRI examinations are associated with a significantly higher rate of BI-RADS category 3 assessments than are nonbaseline examinations. Most cancers diagnosed at follow-up of BI-RADS 3 lesions are in an early stage and are diagnosed at or before the 6-month follow-up examination. When used judiciously, short-interval follow-up MRI is an appropriate method for identifying early-stage breast cancer while avoiding unnecessary biopsies with benign findings.
引用
- Edmonds CE, Lamb LR, Mercaldo SF, et al. Frequency and Cancer Yield of BI-RADS Category 3 Lesions Detected at High-Risk Screening Breast MRI. AJR Am J Roentgenol. 2019. PMID: 31799867. doi:10.2214/AJR.19.21778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。